TRVIライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (18 5月 2024 @ 05:00):

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions...

Stats
本日の出来高	64 935.00
平均出来高	256 709
時価総額	195.11M
EPS	$0 ( 2024-05-09 )
次の収益日	( $-0.110 ) 2024-08-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-8.15
ATR14	$0.0120 (0.43%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-10	Good Jennifer L	Buy	4 578	Common Stock
2024-05-10	Good Jennifer L	Sell	4 578	Common Stock
2024-05-10	Good Jennifer L	Sell	4 578	Stock Option (right to buy)
2024-02-15	Galletta Christopher	Buy	28 500	Stock Option (right to buy)
2024-02-15	Simon Farrell	Buy	175 000	Stock Option (right to buy)

INSIDER POWER
79.66
Last 98 transactions
Buy: 24 441 332 \| Sell: 1 388 191

ボリューム相関

長: 0.13 (neutral)

短: -0.54 (weak negative)

Signal:(42.223) Neutral

Trevi Therapeutics Inc 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Trevi Therapeutics Inc 相関 - 通貨/商品

0.49
( neutral )

-0.15
( neutral )

0.00
( neutral )

-0.33
( neutral )

-0.55
( weak negative )

-0.39
( neutral )

Trevi Therapeutics Inc 財務諸表

Annual	2023
収益:	$0
総利益:	$-123 000 (0.00 %)
EPS:	$-0.290

FY	2023
収益:	$0
総利益:	$-123 000 (0.00 %)
EPS:	$-0.290

FY	2022
収益:	$0
総利益:	$-43 000.00 (0.00 %)
EPS:	$-0.450

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-1.830

Financial Reports:

No articles found.

Trevi Therapeutics Inc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Trevi Therapeutics Inc

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.